This phase II trial studies how well pembrolizumab works in treating patients with stage IB-IV mycosis fungoides. Antibodies, such as pembrolizumab, may interfere with the ability of cancer cells to grow and spread.
To evaluate the antitumor activity of pembrolizumab in patients with advanced mycosis fungoides (MF) as initial systemic therapy.
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
Please refer to this study by its ClinicalTrials.gov identifier: NCT03695471